An Open-Label, Repeated-Dose Trial to Characterize the Efficacy and Safety, and Impact on Quality of Life Measures of Dilaudid CR [hydromorphone controlled-release] in Patients With Chronic Low Back Pain.
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2009
At a glance
- Drugs Hydromorphone (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors ALZA Corporation
- 21 Jul 2009 Actual end date (Nov 2001) added as reported by ClinicalTrials.gov.
- 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2009 Actual patient number (207) added as reported by ClinicalTrials.gov.